info@hoththerapeutics.com Our Pipeline
  • X
  • Instagram
Hoth Therapeutics
  • X
  • Instagram
  • Home
  • About
    • About Hoth
    • A Letter From Our CEO
    • Our Team
    • Scientific Advisory Board
    • Careers
  • For Patients
    • For Patients
    • Expanded Access Program
    • Clinical Trials
    • Oncology
    • Neurology
    • Inflammatory
    • Dermatology
    • Pipeline
  • Partnering
    • University Collaborations
    • Partnering With Hoth
  • Investors/Media
  • Contact
Select Page

SITE MAP

Pages

  • About us
    • Board of Directors
    • Our Team
      • Adam Friedman, M.D., F.A.A.D.
      • Carla Yuede, Ph.D.
      • David B. Sarnoff
      • David Briones
      • Glenn Cruse, Ph.D.
      • Graig Springer
      • Hayley Springer
      • John Cirrito, Ph.D.
      • Mario Lacouture, M.D.
      • Michael Peters, Ph.D.
      • Robb Knie
      • Wayne Linsley
      • William Weglicki, M.D.
    • Scientific advisory board
      • Jonathan Hale Zippin M.D., Ph.D.
  • Careers
  • CLEER-001 Phase 2A Clinical Trial
  • Clinical Trials
  • Contact us
  • Dermatology
  • Expanded Access & Compassionate Use
  • Expanded Access Policy and Eligibility Criteria
  • For Patients
  • Home
  • Inflammatory
  • Letter From Our CEO
  • Neurology
  • Oncology
  • Partnering
  • Partnering With Hoth
  • Pipeline
  • PRIVACY POLICY
  • Site map
  • Terms & Conditions


Posts

No posts found.

Helpful Links

  • Home
  • Investors
  • About Us
  • Our Team
  • Contact Us

Contact
(646) 756-2997
info@hoththerapeutics.com

About
Hoth Therapeutics

At Hoth Therapeutics, we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing.

Contact
(646) 756-2997
info@hoththerapeutics.com

Follow Us


  • Twitter

  • Instagram
© 2022 Hoth Therapeutics. All Rights Reserved
Terms & ConditionsPrivacy PolicySite Map